The GPT-2 antibody is a specialized tool developed to study the function and regulation of the GPT-2 (glutamic-pyruvate transaminase 2) enzyme, also known as alanine aminotransferase 2 (ALT2). This enzyme plays a critical role in amino acid metabolism, particularly in the conversion of alanine and α-ketoglutarate to pyruvate and glutamate, a process vital for gluconeogenesis and energy homeostasis. GPT-2 is expressed in various tissues, including the liver, kidney, and brain, and has been implicated in metabolic disorders, neurodegenerative diseases, and cancer progression. Antibodies targeting GPT-2 enable researchers to detect its expression levels, localize it within cells, and investigate its interaction with other biomolecules. Such tools are essential for understanding its physiological and pathological roles, including its potential as a biomarker for liver injury or metabolic syndrome. Studies using GPT-2 antibodies have contributed to insights into tissue-specific metabolic adaptations and disease mechanisms. However, challenges remain in distinguishing GPT-2 from its isoform GPT-1 (ALT1) due to structural similarities. Ongoing research focuses on refining antibody specificity and exploring therapeutic applications, such as targeting GPT-2 in metabolic dysregulation or cancer. These efforts highlight the antibody’s importance in bridging molecular biology with clinical diagnostics and treatment strategies.